Clinical Integrative Research Center of Atlanta, Panda Neurology | Atlanta, GA

Research site

Location

5887 Glenridge Dr., Suite 140, Atlanta, Georgia, United States of America

Site insights

Top conditions

Top treatments

Soticlestat

ZX008

Cannabidiol

Eslicarbazepine Acetate

Fenfluramine Hydrochloride

Galcanezumab

Amitriptyline

334

Ubrogepant

AMG 334

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Contact this site

Cristy Miles

Verified by this site

Active trials

7 of 20 total trials

A Study of Galcanezumab (LY2951742) in Participants 6 to 17 Years of Age With Episodic Migraine (REBUILD-1)

The main purpose of this study is to evaulate the efficacy and safety of galcanezumab in participants 6 to 17 years of age for the preventive treatme...

Enrolling

Episodic Migraine

Drug: Galcanezumab

Drug: Placebo

A Study of Soticlestat as an Add-on Therapy in Children and Adults With Dravet Syndrome or Lennox-Gastaut Syndrome

The main aim of the study is to learn if soticlestat, when given as an add-on therapy, reduces the number of seizures in children and adults with Dra...

Active, not recruiting

Dravet Syndrome (DS)

Lennox Gastaut Syndrome (LGS)

Drug: Soticlestat

A Study to Investigate the Long-Term Safety of ZX008 (Fenfluramine Hydrochloride) Oral Solution in Children and Adults With Epileptic Encephalopathy Including Dravet Syndrome and Lennox-Gastaut Syndrome

This is an international, multicenter, open-label, long-term safety study of ZX008 in subjects with Dravet syndrome, Lennox-Gastaut syndrome or epile...

Active, not recruiting

Epileptic Encephalopathy

Dravet Syndrome

Drug: ZX008 (Fenfluramine Hydrochloride)

Evaluation of SPN-812 (Viloxazine Extended-release Capsule) in Preschool-age Children With ADHD

This study will evaluate the efficacy and safety of SPN-812 (viloxazine extended release) in children 4 to 5 years of age with ADHD.

Enrolling

Attention-Deficit/Hyperactivity Disorder

Drug: Placebo

Drug: 100mg SPN-812

Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Pediatric Participants (Ages 6-17)

Migraine is a common neurological disorder typically characterized by attacks of throbbing, moderate to severe headache, often associated with nausea...

Invitation-only

Migraine

Drug: Ubrogepant

Randomized, Double-Blind Study to Evaluate Efficacy and Safety of Cenobamate Adjunctive Therapy in PGTC Seizures

This trial is intended to study the safety and effectiveness of an new anti-epileptic drug (AED) on Primary Generalized Tonic-Clonic (PGTC) Seizures....

Active, not recruiting

Primary Generalized Epilepsy

Drug: Cenobamate

Drug: Placebo

Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) (Ubro Peds)

Migraine is a common neurological disorder typically characterized by attacks of throbbing, moderate to severe headache, often associated with nausea...

Enrolling

Migraine

Drug: Placebo-Matching Ubrogepant

Drug: Ubrogepant